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Background: Bevacizumab, a recombinant humanized monoclonal antibody for vascular endothelial growth factor,
has been widely used in various cancers offering substantial clinical benefit. It is reportedly associated with development
of high-grade proteinuria and nephrotic syndrome with the histology of thrombotic microangiopathy, but there has
been no report describing the development of immunoglobulin A nephropathy in bevacizumab-treated patients.
Case presentation: A 68-year-old man with metastatic rectal cancer was treated with bevacizumab. He presented with
hematuria and proteinuria 15 and 17 months, respectively, after bevacizumab initiation. Bevacizumab was stopped at
17 months. Renal biopsy at 19 months revealed immunoglobulin A nephropathy, with numerous paramesangial
hemispherical deposits and thrombotic microangiopathy. Electron microscopy showed numerous paramesangial
electron-dense deposits of various sizes, and subendothelial injuries. Proteinuria almost completely resolved
8 months after bevacizumab cessation, although hematuria persisted. Follow-up renal biopsy 11 months after
bevacizumab cessation showed a marked decrease in mesangial immunoglobulin A deposits and paramesangial
electron-dense deposits, which correlated with a gradual decrease in serum immunoglobulin A.
Conclusion: This is the first case report that confirmed histologically the development and resolution of
immunoglobulin A nephropathy during and after bevacizumab therapy. This case shows that there may be
other mechanisms of glomerular injury by bevacizumab besides glomerular endothelial injury leading to
thrombotic microangiopathy.
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A nephropathyBackground
Vascular endothelial growth factor (VEGF) is an en-
dogenous glycoprotein that plays a critical role in the
growth of blood vessels [1]. Bevacizumab, a recom-
binant humanized monoclonal antibody for VEGF, inhibits
tumor angiogenesis, and the addition of bevacizumab to
chemotherapy is effective in the treatment of advanced or* Correspondence: sjun@chuo-hp.jp
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reproduction in any medium, provided the ormetastatic cancers, including breast cancer, colorectal can-
cer, and non-small cell lung cancer, renal cell carcinoma,
and glioblastoma multiforme [2]. However, the addition of
bevacizumab to chemotherapy increases the risk of high-
grade proteinuria and nephrotic syndrome [3]. Eremina
et al. [4] reported that thrombotic microangiopathy
(TMA) was common in patients treated with bevacizu-
mab and that, in human renal biopsy specimens and an
animal model, a decrease in glomerular VEGF induced
direct damage of the glomerular endothelium.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tal cancer treated with bevacizumab, who developed
nephrotic syndrome with the histology of immunoglobulin
(Ig) A nephropathy with massive paramesangial deposits,
along with mild TMA. Proteinuria resolved following beva-
cizumab cessation, and marked decreases in both IgA and
paramesangial electron-dense deposits (EDDs) were con-
firmed by follow-up biopsy 11 months after bevacizumab
cessation.
Case presentation
A 68-year-old man with no remarkable medical history
underwent rectal low anterior resection in November
2008 for Stage T3N0M0 rectal cancer. In December 2009,
pulmonary metastasis was found and capecitabine, oxali-
platin, and bevacizumab treatment (400 mg every 3 weeks)
initiated. At chemotherapy initiation, his serum creatinine
was 0.66 mg/dl. Urinalysis was done every month after
the initiation of chemotherapy, but neither proteinuria
nor hematuria was evident. In March 2011 (15 months
after chemotherapy initiation), dipstick urine evaluation
first demonstrated hematuria of 1–2+. Proteinuria was
evident for 2 months afterward. Subsequently, chemo-








White blood cells 3.17 × 103/μl
Red blood cells 3.78 × 106/μl
Hemoglobin 13.0 g/dl
Hematocrit 38%
Platelets 64 x 103/μl
Red blood cell fragmentation (−)
Biochemistry
Urea nitrogen 9.4 mg/dl
Serum creatinine 0.65 mg/dl
Uric acid 6.0 mg/dl
Total protein 4.8 g/dl
Serum albumin 2.2 g/dl
Total choresterol 198 mg/dl
Foot notes of Table 1.
dsDNA, double-stranded deoxyribonucleic acid antibody.heavy proteinuria persisted, and the patient was referred
to us in July 2011. He had gained 6 kg of body weight and
had developed edema of the lower extremities over the
preceding month. His blood pressure was 135/80 mm Hg.
Laboratory investigations are listed in Table 1. Urinalysis
showed proteinuria of 3.5 g/day and >100 red blood cells/
high-power field (HPF), with granular and fatty casts.
Marked hypoproteinemia and hypoalbuminemia were
observed, but serum creatinine was normal. Serum IgA
was elevated to 487 mg/dl (normal: 110–410 mg/dl).
Serum complement component (C) 3 and C4, total serum
hemolytic activity, and hepatobiliary function were nor-
mal. Tests for hepatitis B and C, antinuclear antibody,
anti–double-stranded deoxyribonucleic acid antibody, and
cryoglobulins were all negative. Carcinoembryonic antigen
(CEA) was elevated to 11.5 ng/ml (normal: <5 ng/ml),
but carbohydrate antigen 19–9 was within normal range.
No red blood cell fragmentation was observed. Com-
puted tomography showed normal-sized kidneys, massive
ascites, and bilateral pleural effusion, and a small, isolated
pulmonary metastatic lesion was observed in the right in-
ferior lobe.
Percutaneous renal biopsy was performed. Three out
of forty-three glomeruli were globally sclerotic. OtherTriglycerides 154 mg/dll
Asparate aminotransferase 40 IU/l
Alkaline phosphatase 32 IU/l
Lactate hedydrogenase 230 IU/l
Serology
Immunoglobulin G 571 mg/dl
Immunoglobulin A 487 mg/dl
Immunoglobulin M 66 mg/dl
Total serum hemolytic activity 41.8 U/ml
Complement component 3 81 mg/dl




Hepatitis B virus antigen (−)
Hepatitis C virus antibody (−)
Tumor marker
Carcinoembryonic antigen 11.5 ng/ml
Carbohydrate antigen 19-9 < 2.0 U/ml
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tion, with periodic acid-Schiff (PAS)-positive paramesan-
gial hemispherical deposits. Capillary lumens were dilated
and occupied by PAS-positive material. Mesangiolysis was
also observed in some glomeruli (Figures 1A and B).
Tubular atrophic and interstitial fibrotic changes were ob-
served focally. Arterial vessels showed mild sclerosis, with
no intra-arterial or intra-arteriolar thrombi. Immunofluor-
escence (IF) study revealed marked intensity (+++) for IgA
(Figure 1C) and C3, and slight intensity (+) for IgG, IgM,
C1q, and fibrinogen, which were found mainly in the
mesangium and along capillary walls. Electron microscopy
revealed numerous EDDs in paramesangial areas, which
were fine granular, spherical, or hemispherical in shape
and varying in size (Figure 2A). Similar EDDs were ob-
served in some subendothelial areas. In addition, suben-
dothelial electron-lucent widening with loose granular
materials was observed focally and segmentally. Some
glomerular capillary lumens were occupied with globular
and loose materials, which were thought to be serum
components. These materials gathered in subendothelial
areas, compressing endothelial cells to the opposite side
(Figure 2B).
The patient underwent follow-up for nephrotic syn-
drome with unremarkable therapy. Heavy proteinuriaA
C
Figure 1 Light microscopy findings at the first biopsy. (A) Many period
observed, and hyaline-like materials occupied dilated capillary lumens. At the n
areas were markedly widened, and filled with hyaline-like materials, whic
(C) Strong IgA deposition was observed in the mesangium and along capil
acid-methenamine-silver staining; original magnification 400×.with hematuria continued after bevacizumab cessation,
but began to decrease gradually after 6 months. Eight
months later, proteinuria had decreased to 0.3 g/g · cre-
atinine, and serum total protein and albumin were 7 g/dl
and 4 g/dl, respectively. However, hematuria persisted.
In June 2012, a second renal biopsy was performed to
reevaluate renal histology. At the second biopsy, serum
creatinine was 1.09 mg/dl with negative urinary protein
and urinary red blood cells of 20–29/HPF (Table 2).
Total protein and serum albumin were normalized, and
serum IgA had decreased from 487 mg/dl at the first bi-
opsy to 297 mg/dl. Four out of twenty-nine glomeruli
were globally sclerotic. Other glomeruli exhibited mild
mesangial proliferation only (Figure 3A). Tubular atro-
phy and interstitial fibrosis were present in approxi-
mately 30% of the tubulointerstitial area (Figure 3B).
IF revealed mild intensity (+) for IgA (Figure 3C) and C3,
decreased compared with the first biopsy. On electron
microscopy, EDDs in the mesangium were decreased
in number and size compared with the first biopsy
(Figure 3D). Widening of subendothelial spaces and
subendothelial EDDs were still observed segmentally (data
not shown).
The pulmonary metastatic lesion showed only slight en-
largement, and no new metastatic lesions were identified.B
ic acid-Schiff (PAS) positive paramesangial hemispherical deposits were
ine o’clock position, mesangiolysis was also observed. (B) Subendothelial
h were stained weaker than paramesangial hemispherical deposits.
lary walls. (A) PAS staining; original magnification 400×. (B) Periodic
A B
3 µm 5 µm
Figure 2 Electron microscopy findings at the first biopsy. (A) Numerous paramesangial electron-dense deposits (EDDs) of various sizes and
segmental widening of subendothelial areas with electron-lucent materials were evident (arrows). (B) Giant globular materials widened the suben-
dothelial space remarkably and compressed endothelial cells to the opposite side (arrows). Paramesangial and subendothelial EDDs were also
seen in the lower and upper parts of the photograph, respectively.
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ated at the end of October 2012 because CEA grad-
ually increased to 11.4 ng/ml. In December 2012,
laboratory data showed no proteinuria, urinary blood
cells of 10–15/HPF, serum creatinine of 0.82 mg/dl,
and serum IgA of 280 mg/dl. At the final follow-up
in July 2013, hematuria first disappeared, and serum cre-
atinine and serum IgA were 0.84 mg/dl and 270 mg/dl,




Urinary red blood cells 20-29/HPF
Casts (−)
Biochemistry
Urea nitrogen 21.6 mg/dl
Serum creatinine 1.09 mg/dl
Uric acid 7.5 mg/dl
Total protein 6.9 g/dl
Serum albumin 4.5 g/dl
Serology
Immunoglobulin G 928 mg/dl
Immunoglobulin A 297 mg/dl
Immunoglobulin M 57 mg/dlConclusions
Our patient was diagnosed with bevacizumab-induced IgA
nephropathy with massive paramesangial deposits because
of the following:
 neither proteinuria nor hematuria were identified by
medical checkups performed prior to bevacizumab
treatment
 urinary abnormalities first appeared 14 months after
bevacizumab initiation
 proteinuria disappeared, and hematuria decreased,
after bevacizumab cessation and
 IgA deposition and paramesangial EDDs were
markedly decreased at the second biopsy, 10 months
after bevacizumab cessation
TMA, characterized by subendothelial widening with
loose granular materials, was also evident in our patient.
Bevacizumab, a recombinant humanized monoclonal
antibody for VEGF, inhibits VEGF-induced angiogenesis
and tumor growth [5]. Anti-VEGF agents are generally
well tolerated, but hypertension and asymptomatic protein-
uria are common dose-related adverse effects, frequently
occurring together [6]. The incidence of proteinuria ranges
from 21%–63% [6]. Although this proteinuria is largely
asymptomatic and low-grade, nephrotic-range protein-
uria occurs in 1%–2% of bevacizumab-treated patients
[7]. VEGF is constitutively expressed on podocytes, and
its receptors exist on glomerular capillary endothelial





Figure 3 Light and electron microscopy findings at the second biopsy. (A) Mild mesangial proliferation was seen, but neither definite
paramesangial hemispherical deposits nor widened subendothelial spaces were evident. (B) Two glomeruli showed mild mesangial proliferation.
However, two glomeruli were globally sclerotic and one had collapsed (ten o’clock position); in addition, tubular atrophy and interstitial fibrosis
was evident around these glomeruli. (C) The degree of IgA deposition had clearly decreased compared with the first biopsy. (D) Electron-dense
deposits in the mesangium and subendothelial area were obviously decreased compared with the first biopsy. (A) Periodic acid-Schiff (PAS) staining;
original magnification 300×. (B) Elastica Masson staining; original magnification 100×.
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tion by podocytes. VEGF decrease causes the injury of
fenestration of the endothelium, promoting the devel-
opment of endothelial injuries [4]. These findings sug-
gest that VEGF decrease compromises the glomerular
capillary permeability barrier.
Table 3 shows biopsy-documented glomerular disease
in 15 bevacizumab-treated patients, including our case
[4,5,9-14]. The period from bevacizumab initiation to glo-
merular disease onset ranged from 2 weeks to 15 months.
Eight patients exhibited nephrotic syndrome. Nine patients
were followed-up after bevacizumab cessation, and all ex-
cept one experienced decrease or resolution of proteinuria.
Histologically, TMA was evident in 12 patients: two in
whom it was superimposed on collapsing glomerulopathy
or mesangial proliferative glomerulonephritis (GN; our
case), one with collapsing glomerulopathy alone, one
with cryoglobulinemic GN, and one with focal proliferative
immune complex GN (IgM-type). Of the 12 patients with
TMA, predominant glomerular IgA deposition was ob-
served in five, including our case [4,9,13]. In two of these
cases, EDDs were absent. IgA deposition in these patients
could be nonspecific; for example, it could be caused by
IgA trapped by damaged capillary walls [12]. In one patientwith renal cell carcinoma [9], IgA-dominant glomerular
deposition was found at renal biopsy, although no IgA
deposition was evident in tissue samples obtained during
nephrectomy before bevacizumab treatment. However,
EDDs were mainly distributed in widened subendothelial
areas associated with mesangial cell interposition. These
histological features and the absence of hematuria, which
were inconsistent with IgA nephropathy, led to a diagnosis
of IgA-predominant immune complex GN rather than
IgA nephropathy [9]. In another patient [4], EDDs were
observed mainly in subendothelial areas and segmentally
in the mesangium. In our case, the first symptom was
hematuria, which was followed by proteinuria. Histologi-
cally, IF revealed IgA deposition mainly in the mesangium,
along with EDDs and numerous paramesangial hemispher-
ical deposits, which are characteristic of IgA nephropathy
[15]. After bevacizumab cessation, these deposits markedly
decreased, with the resolution of proteinuria and decreased
hematuria. Interestingly, sorafenib, another human mono-
clonal antibody for VEGF, was reported to cause a rapid
deterioration of renal function and a marked increase of
proteinuria in pre-exising IgA nephropathy [16]. Chrono-
logical changes of our and the reported cases emphasize
the close relationship between anti-VEGF effect and IgA
Table 3 Biopsy-documented cases with glomerular disease by bevacizumab
Reference Age (years)/
gender
Onset Proteinuria Hematuria LM IF EM Follow-up
4 59/M 9 mo 3.4 g/gCr ND Glomerular TMA ND FPE Proteinuria
decreased
4 74/M 3 mo 2.7 g/gCr ND Glomerular TMA ND FPE Proteinuria
decreased
4 56/M 7 mo 0.16 g/day ND Glomerular TMA ND Focal FPE Dead shortly
thereafter
4 62/M 3 mo 0.5 g/dl + Glomerular TMA IgA, MES Fibrin, SEn and MES Proteinuria
resolved
4 61/M 5 mo 4.6 g/day ND Glomerular TMA ND Focal podocyte injuries ND




5 70/M 2 w 6.0 g/gCr ND Glomerular TMA No ND Proteinuria
decreased
9 59/M 15 mo 6.9 g/day − Glomerular TMA IgA, MES and
capillary
EDDs, sparsely SEn Proteinuria
decreased
10 ND/ND ND Nephrotic ND Cryo-GN ND ND ND
11 ND/F ND Nephrotic ND Collapsing GP ND ND ND
12 69/F 3 mo 3.6 g/day − Glomerular TMA+
collapsing GP




13 71/M 1 mo 9.6 g/day ND Focal PGN C3 and IgM, MES
and capillary
EDDs, sparsely SEn Proteinuria
decreased
14 ND/M 3 mo 3.4 g/gCr ND Glomerular TMA ND ND ND
14 ND/ND 1 mo 3.2 g/gCr ND Glomerular TMA ND ND ND
Present case 64/M 14 mo 3.5 g/day + MES PGN + TMA IgA, MES and
capillary
EDDs, MES and SEn Proteinuria
resolved
Foot notes of Table 3.
Onset means the duration form the start of bevacizumab to the appearance of urinary abnormalities.
M, male, F, female, LM, light microscopy, Cr, serum creatinine, IgA, immunoglobulin A, IgM, immunoglobulin M, C3, serum complement component 3,
IF, immunofluorescence, EM, electron microscopy, TMA, thrombotic microangiopathy, MES, mesangial, SEn, subendothelial, Cryo-GN, cryoglobulinemic
glomerulonephritis, GP, glomerulopathy, PGN, proliferative glomerulonephritis, FPE, foot process effacement, EDDs, electron dense deposits, ND, not
documented, mo, month(s), w, week(s).
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erular and tubulointerstitial sclerotic changes evident at
the first biopsy had clearly progressed at the second, asso-
ciated with increased serum creatinine (0.66 mg/dl at the
first biopsy and 1.09 mg/dl at the second), despite the
fact that proteinuria had resolved and hematuria had
decreased at the second biopsy. This may be because IgA
nephropathy remained “active” during the first 6 months
after bevacizumab cessation. No decrease in proteinuria
and hematuria during the first 6 months supports this
possibility.
The mechanisms by which bevacizumab caused IgA
nephropathy are unknown. It is easy to eliminate the
possibility that IgA immune deposits comprised the bev-
acizumab–VEGF immune complex, because bevacizu-
mab is a recombinant humanized murine antibody of
the IgG1 subclass [12], and IgG deposition in this case
was very mild. One possibility is that circulating IgA im-
mune complexes accumulated in the mesangium and
subendothelial areas through capillary walls damaged bybevacizumab. However, the accumulation of IgA immune
complexes may depend on factors unique to each patient,
such as the amount of circulating IgA immune complexes,
the presence or absence of chronic mucosal inflammation,
or environmental factors, because not all patients with
bevacizumab-induced TMA exhibited glomerular IgA de-
position. In our case, serum IgA gradually decreased after
bevacizumab cessation (512, 295, 277, and 270 mg/dl at 1,
12, 15, and 25 months after cessation, respectively). To
date, no reports describe serum IgA in bevacizumab-
induced renal diseases. Although the effect of bevacizu-
mab on the immune system is unclear, further analyses of
bevacizumab and serum IgA are warranted, as bevacizu-
mab reportedly affects the permeability of gastroduodenal
and intestinal mucosa [17], which is known to produce
mucosal IgA [18] and to be closely associated with IgA ne-
phropathy development [19].
In conclusion, this is the first case report that con-
firmed histologically the development and resolution of
IgA nephropathy during and after bevacizumab therapy.
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troduodenal and intestinal mucosa might be related to
the IgA nephropathy development, further studies and
accumulation of cases are warranted to elucidate the
exact mechanism.
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for the publication of this case report and accompanying
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